BEVERLY HILLS

Study on Foot-and-Mouth Disease Virus Results in Submission for Additional EPA Label

Retrieved on: 
Monday, March 11, 2024
Hydrogen, DARPA, Hospital, Restaurant, Hydrogen peroxide, Livestock, Disinfectant, Food safety, Research, Deer, Annual report, Stainless steel, DHS, Animal, Sheep, Goat, Global health, FMD, Meat, Contagious disease, Foot-and-mouth disease virus, COVID-19, School, Virus, FMDV, TAD, EPA, Decontamination, Infection, Police, Science, PIADC, Foot-and-mouth disease, Pharmaceutical industry

This significant advancement supports the Company’s submission for an additional EPA label.

Key Points: 
  • This significant advancement supports the Company’s submission for an additional EPA label.
  • Foot-and-mouth disease (FMD) represents a critical global threat, being an extremely contagious disease affecting a wide range of cloven-hoofed animals including cows, pigs, sheep, goats, and deer.
  • TOMI’s recent study has proven SteraMist iHP technology to eliminate infectious FMDV from both porous (concrete) and non-porous (stainless steel) surfaces in the presence of organic soil load.
  • Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

PodcastOne (NASDAQ: PODC) Subsidiary of (NASDAQ: LVO) President and Co-Founder Kit Gray to Present at the 36th Annual ROTH Conference March 17-19, 2024

Retrieved on: 
Friday, March 8, 2024
PODC, Q&A, LiveOne, Annual, LVO, Conference

LOS ANGELES, CA, March 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – PodcastOne (NASDAQ: PODC), a leading podcast platform and a subsidiary of LiveOne ( NASDAQ: LVO ) announced today that PodcastOne’s President and Co-Founder Kit Gray will present at the 36th Annual ROTH Conference from March 17-19, 2024 in Dana Point, CA.

Key Points: 
  • LOS ANGELES, CA, March 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – PodcastOne (NASDAQ: PODC), a leading podcast platform and a subsidiary of LiveOne ( NASDAQ: LVO ) announced today that PodcastOne’s President and Co-Founder Kit Gray will present at the 36th Annual ROTH Conference from March 17-19, 2024 in Dana Point, CA.
  • The Annual ROTH Conference, one of the largest in the nation for small-cap companies, combines company presentations, Q&A sessions and management 1-on-1 meetings.
  • The conference provides investors the opportunity to participate in one-on-one and small group meetings, analyst-selected fireside chats, industry keynotes and panels.
  • To submit your ROTH Conference registration request, click here .

TOMI Expands SteraMist iHP Corporate Service Contracts and Clients

Retrieved on: 
Thursday, March 7, 2024
Hydrogen, DARPA, Acquisition, Pfizer, Hospital, Rocky, Restaurant, Hydrogen peroxide, Food safety, Disinfectant, Annual report, Health, Growth, Cell, Monroe Dunaway Anderson, Horsepower, Meat, University, School, Supervisor, Decontamination, MD Anderson Cancer Center, Police, Medication, Trust, Paint, Corporation, Partnership

FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.

Key Points: 
  • FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.
  • SteraMist iHP technology is becoming the standard decontamination technology in the life sciences sector and academic institutions with a broad spectrum of clients equipped with mobile systems, custom integrations, and service contracts.
  • In a notable development, Rising Pharmaceuticals has entered into an ongoing annual contract with TOMI’s SteraMist iHP Corporate Service following the acquisition of a building previously serviced by the team.
  • SteraMist iHP Corporate Service managed to decontaminate our entire facility quickly without causing harm to the infrastructure or our sensitive equipment.

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Wednesday, March 6, 2024
MRI, Therapy, SAN, Biotechnology, Skeleton, FDA, DMD, Duchenne muscular dystrophy, Conference, Patient, OLE, Cardiac muscle, Exosome, MDA, LVEF, Episcopal conference, PUL, Pharmaceutical industry

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.
  • CAP-1002 revealed clinically meaningful improvements in ameliorating cardiac function.
  • “We are pleased to be presenting our positive long-term open label extension data at this year’s MDA Conference,” said Linda Marbán, Ph.D., chief executive officer of Capricor.
  • These two-year results suggest that CAP-1002 has the potential to slow the decline of DMD progression and speaks to the potential long-term benefit for patients.

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Jackie Schimmel's The Bitch Bible Podcast, Further Strengthening PodcastOne’s Thriving Network of Female Focused Programming

Retrieved on: 
Monday, March 4, 2024
Acquisition, Sony Television, Dares Phrygius, Television, Woman, LOS, IHeartRadio, NBCUniversal, News, PODC, Culture, Thought, Growth, Female, The Adam Carolla Show, HuffPost, 3 Arts Entertainment, Food, Blog, Universal, Human, NBC, Apple Podcasts, Entertainment Weekly, Mama, Intuition, Jackie, Amazon, Schimmel, UCLA, Creative Artists Agency, Publication, LVO, Partnership, Music

LOS ANGELES, CA, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – PodcastOne (NASDAQ: PODC), a leading podcast platform and a subsidiary of LiveOne (NASDAQ: LVO), which owns ~73% of the PODC outstanding common stock, announced today that it has acquired the exclusive sales and distribution rights to Jackie Schimmel’s The Bitch Bible Podcast. This acquisition allows the podcast to immediately become a cornerstone of PodcastOne’s flourishing and growing network of programming for women.

Key Points: 
  • This acquisition allows the podcast to immediately become a cornerstone of PodcastOne’s flourishing and growing network of programming for women.
  • As part of the newly announced partnership, Schimmel will begin to create video elements as a companion to her audio-based podcast.
  • “PodcastOne is thrilled to welcome Jackie and The Bitch Bible to the network.
  • PodcastOne shows are available through PodcastOne , Apple Podcasts, Spotify, iHeart, Amazon and wherever podcasts are heard.

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Vaccine, Project, Webcast, Exosome, Protein, Poster, Mouse, Infection, Liver, Bangladesh Technical Education Board, Biotechnology, NIAID, Marketing, File, BLA, Therapy, Congress, PPMD, PUL, WMS, CMC, Distribution, International, Regenerative medicine, ID, Duchenne muscular dystrophy, Safety, Dicarboxylic acid, Biologics license application, IND, Commercialization, SARS-CoV-2, Lipid, Messenger, MicroRNA, Inflammation, FDA, Food, DMD, Priority review, Cell, COVID-19, Report, Patient, Oligonucleotide, PRV, Kidney, Tissue, Pharmaceutical industry

Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.

Key Points: 
  • Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.
  • Next steps for Cohort A: plan to report top-line data in the fourth quarter of 2024.
  • Revenues for the fourth quarter of 2023 were approximately $12.1 million compared with approximately $1.0 million for the fourth quarter of 2022.
  • Operating expenses: Total operating expenses for the fourth quarter of 2023 were approximately $13.2 million compared with approximately $9.0 million for the fourth quarter of 2022.

Barfresh Provides Fourth Quarter and Full Year 2023 Results and Business Update

Retrieved on: 
Thursday, February 29, 2024
Engineering, Twist, Marketing, Growth, Adjustment, GAAP, COVID, Research, Video game

LOS ANGELES, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, is providing a business update for the full year ended December 31, 2023.

Key Points: 
  • Gross margins for the fourth quarter of 2023 were 33%, compared to 36% for the fourth quarter of fiscal year 2022.
  • Net loss for the fourth quarter of 2023 was $701,000, as compared to a loss of $1.9 million in the fourth quarter of 2022.
  • Selling, marketing and distribution for the fourth quarter of 2023 was $624,000, compared to $625,000 in the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 decreased 31% to $629,000 compared to $912,000 in the fourth quarter of 2022.

TOMI Environmental Announces Additional iHP Custom Engineered System Installation Contracted for California

Retrieved on: 
Thursday, February 29, 2024
Hydrogen, ISO, DARPA, Hospital, Restaurant, Hydrogen peroxide, Disinfectant, Annual report, ISPE, Growth, GMP, Ionization, Horsepower, Meat, School, COVID-19, Automation, Decontamination, CES, Police, Laboratory

FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company.

Key Points: 
  • FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company.
  • The contracted iHP Custom Engineered System (CES) is valued at approximately $600,000.
  • Following a presentation by Dr. Halden Shane, CEO of TOMI, at an ISPE event hosted by Avid Bioservices, the contractors recognized the benefits of the automated iHP Custom Engineered System showcased in Avid's new facility and brought SteraMist iHP to the customer as an option.
  • Shane, COO of TOMI states, “We’re pleased to announce this new CES contract and look forward to continuing our growth momentum.

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

Retrieved on: 
Tuesday, February 27, 2024
Therapy, SAN, Regenerative Medicine Advanced Therapy, Biotechnology, Chemistry, FDA, DMD, Duchenne muscular dystrophy, BLA, Phase 3, Patient, Biologics license application, Exosome, CMC, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March.

Key Points: 
  • SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March.
  • In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls (CMC) plans for commercial launch, if approved which may enable opportunities to expedite the pathway to a Biologics License Application (BLA) submission.
  • The Company has previously been granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designations for the use of CAP-1002 in Duchenne muscular dystrophy (DMD) and these designations enable sponsors to work closely with the FDA and receive its guidance on potential expedited pathways for approval.
  • “At Capricor, we remain focused on getting to approval as quickly as possible and we look forward to providing more details after this meeting.”

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

Retrieved on: 
Thursday, February 22, 2024
Therapy, SAN, Exosome, Biotechnology, Webcast

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024.

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024.
  • Management will then host a webcast and conference call at 4:30 p.m.
  • ET on February 29.